Health Care & Life Sciences » Biotechnology | Dynavax Technologies Corp.

Dynavax Technologies Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
66,720.00
90,722.00
106,794.00
112,444.00
95,154.00
158,899
Depreciation, Depletion & Amortization
1,327.00
1,404.00
1,365.00
2,257.00
4,438.00
14,483
Other Funds
14,207.00
7,332.00
11,965.00
15,859.00
14,505.00
24,772
Funds from Operations
51,186.00
81,986.00
93,464.00
94,328.00
76,211.00
119,644
Changes in Working Capital
7,663.00
8,248.00
905.00
12,723.00
1,307.00
11,657
Net Operating Cash Flow
58,849.00
73,738.00
92,559.00
107,051.00
77,518.00
131,301
Capital Expenditures
1,629.00
1,667.00
6,970.00
7,757.00
669.00
Purchase/Sale of Investments
49,723.00
92,264.00
78,826.00
94,006.00
108,034.00
Net Investing Cash Flow
51,352.00
90,597.00
85,796.00
86,249.00
108,703.00
Issuance/Reduction of Debt, Net
-
9,559.00
10,988.00
-
-
Net Financing Cash Flow
125,401.00
9,901.00
173,959.00
531.00
187,842.00
Net Change in Cash
15,347.00
26,389.00
4,699.00
20,523.00
2,295.00
Free Cash Flow
60,478.00
75,405.00
99,529.00
114,808.00
78,187.00
Change in Capital Stock
125,401.00
342.00
184,947.00
531.00
187,842.00
Exchange Rate Effect
147.00
371.00
303.00
252.00
674.00

About Dynavax Technologies

View Profile
Address
2929 Seventh Street
Berkeley California 94710
United States
Employees -
Website http://www.dynavax.com
Updated 07/08/2019
Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the development and discovery of novel vaccines and immuno-oncology therapeutics. It focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.